Features
Automated LVEF calculation from standard DICOM echo studies
AI detection of cardiac amyloidosis from A4C and PLAX views
FDA 510(k) clearance for Precision LVEF and Precision Cardiac Amyloid
Prospective randomized controlled trial published in Nature
DICOM-native post-processing (no new hardware or scanners)
PACS and Epic EHR integration
CPT Category III code 0932T for reimbursement (effective Jan 1, 2025)
Breakthrough Device designation and FDA TAP enrollment for cardiac amyloid
Zero marginal clinician burden per study
Multi-indication pipeline (LVEF, amyloid, cirrhosis, reporting, valve disease)
Developed in collaboration with Alexion (AstraZeneca Rare Disease)
Clinically validated in peer-reviewed journals
Precision Cirrhosis for opportunistic liver disease detection
Precision Reporting with EchoPrime foundation model
Multi-valve algorithms (mitral, tricuspid, aortic in development)
Prostate cancer detection and grading (FDA-cleared)
Breast cancer identification and classification (FDA-cleared)
GI tract benign/malignant detection (FDA-cleared)
Pan-cancer detection across multiple tissue types
Molecular biomarker discovery from H&E slides (OmniScreen)
Foundation models: Virchow, Virchow2, Virchow2G, Virchow2G-Mini, PRISM
Custom AI model development services
Regulatory strategy and commercialization support
Voice and text command co-pilot (Paige Alba)
Real-time AI insights during pathology review
Workflow optimization for pathologists
Trained on over 1.5 million slides
Pan-cancer AI modules for therapeutic targeting
Pre-built AI modules for drug discovery
Integration with Philips, Leica, Hamamatsu whole-slide imaging
